209 related articles for article (PubMed ID: 9116756)
1. The E-cadherin cell-cell adhesion pathway in urologic malignancies.
Morton RA; Ewing CM; Watkins JJ; Isaacs WB
World J Urol; 1995; 13(6):364-8. PubMed ID: 9116756
[TBL] [Abstract][Full Text] [Related]
2. Surgical palliation of incurable urologic cancer.
Alagiri M; Greenberg RE
Curr Probl Cancer; 1995; 19(6):360-71. PubMed ID: 8903673
[No Abstract] [Full Text] [Related]
3. Defective E-cadherin function in urological cancers: clinical implications and molecular mechanisms.
Giroldi LA; Bringuier PP; Schalken JA
Invasion Metastasis; 1994-1995; 14(1-6):71-81. PubMed ID: 7657535
[TBL] [Abstract][Full Text] [Related]
4. [Adhesion molecules in urologic tumors].
Heicappell R
Urologe A; 1996 Sep; 35(5):363-9. PubMed ID: 8999627
[TBL] [Abstract][Full Text] [Related]
5. Physical activity and urologic cancers.
Wolin KY; Stoll C
Urol Oncol; 2012 Sep; 30(5):729-34. PubMed ID: 23021556
[TBL] [Abstract][Full Text] [Related]
6. Chromosome 5 suppresses tumorigenicity of PC3 prostate cancer cells: correlation with re-expression of alpha-catenin and restoration of E-cadherin function.
Ewing CM; Ru N; Morton RA; Robinson JC; Wheelock MJ; Johnson KR; Barrett JC; Isaacs WB
Cancer Res; 1995 Nov; 55(21):4813-7. PubMed ID: 7585512
[TBL] [Abstract][Full Text] [Related]
7. Role of complex cadherins in cell-cell adhesion evaluated by spheroid formation in renal cell carcinoma cell lines.
Shimazui T; Schalken JA; Kawai K; Kawamoto R; van Bockhoven A; Oosterwijk E; Akaza H
Oncol Rep; 2004 Feb; 11(2):357-60. PubMed ID: 14719067
[TBL] [Abstract][Full Text] [Related]
8. Multicenter prospective study validating the efficacy of a quantitative assessment tool for frailty in patients with urological cancers.
Soma O; Hatakeyama S; Okamoto T; Fujita N; Hamano I; Tanaka T; Momota M; Yoneyama T; Yamamoto H; Imai A; Yoneyama T; Hashimoto Y; Yoshikawa K; Kawaguchi T; Saitoh H; Nakaji S; Suzuki T; Ohyama C
Med Oncol; 2019 Sep; 36(10):88. PubMed ID: 31520152
[TBL] [Abstract][Full Text] [Related]
9. The cadherin cell-cell adhesion pathway in prostate cancer progression.
Paul R; Ewing CM; Jarrard DF; Isaacs WB
Br J Urol; 1997 Mar; 79 Suppl 1():37-43. PubMed ID: 9088271
[TBL] [Abstract][Full Text] [Related]
10. E-cadherin and associated molecules in the invasion and progression of prostate cancer.
Davies G; Jiang WG; Mason MD
Oncol Rep; 1998; 5(6):1567-76. PubMed ID: 9769407
[TBL] [Abstract][Full Text] [Related]
11. Highlights from the Society of Urologic Oncology, 5th Annual Meeting, December 3-4, 2004, Bethesda, Maryland, United States of America.
Grubb RL; Behari A; Kim CM; Williams CR; Linehan WM; Coleman JA
J Urol; 2005 Dec; 174(6):2330-3. PubMed ID: 16280834
[TBL] [Abstract][Full Text] [Related]
12. Potential role for metformin in urologic oncology.
Sayyid RK; Fleshner NE
Investig Clin Urol; 2016 May; 57(3):157-64. PubMed ID: 27195314
[TBL] [Abstract][Full Text] [Related]
13. Alterations of the cadherin-catenin cell adhesion system in cancers.
Kanai Y; Oda T; Shimoyama Y; Ochiai A; Oyama T; Yoshiura K; Akimoto S; Yamada T; Hirohashi S
Princess Takamatsu Symp; 1994; 24():51-62. PubMed ID: 8983063
[TBL] [Abstract][Full Text] [Related]
14. Inverse relationship between E-cadherin and p27Kip1 expression in renal cell carcinoma.
Migita T; Oda Y; Masuda K; Hirata A; Kuwano M; Naito S; Tsuneyoshi M
Int J Oncol; 2008 Jul; 33(1):41-7. PubMed ID: 18575749
[TBL] [Abstract][Full Text] [Related]
15. E-cadherin mediated adhesion system in cancer cells.
Shiozaki H; Oka H; Inoue M; Tamura S; Monden M
Cancer; 1996 Apr; 77(8 Suppl):1605-13. PubMed ID: 8608551
[TBL] [Abstract][Full Text] [Related]
16. Opposite regulation of epithelial-to-mesenchymal transition and cell invasiveness by periostin between prostate and bladder cancer cells.
Kim CJ; Sakamoto K; Tambe Y; Inoue H
Int J Oncol; 2011 Jun; 38(6):1759-66. PubMed ID: 21468544
[TBL] [Abstract][Full Text] [Related]
17. Reduction of E-cadherin levels and deletion of the alpha-catenin gene in human prostate cancer cells.
Morton RA; Ewing CM; Nagafuchi A; Tsukita S; Isaacs WB
Cancer Res; 1993 Aug; 53(15):3585-90. PubMed ID: 8339265
[TBL] [Abstract][Full Text] [Related]
18. Decreased expression of E-cadherin in the progression of rat prostatic cancer.
Bussemakers MJ; van Moorselaar RJ; Giroldi LA; Ichikawa T; Isaacs JT; Takeichi M; Debruyne FM; Schalken JA
Cancer Res; 1992 May; 52(10):2916-22. PubMed ID: 1581909
[TBL] [Abstract][Full Text] [Related]
19. Gout patients have an increased risk of developing most cancers, especially urological cancers.
Chen CJ; Yen JH; Chang SJ
Scand J Rheumatol; 2014; 43(5):385-90. PubMed ID: 24825466
[TBL] [Abstract][Full Text] [Related]
20. Loss of human E-cadherin (ECD) correlated with invasiveness of transitional cell cancer in the renal pelvis, ureter and urinary bladder.
Wakatsuki S; Watanabe R; Saito K; Saito T; Katagiri A; Sato S; Tomita Y
Cancer Lett; 1996 May; 103(1):11-7. PubMed ID: 8616803
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
